(in thousands)
Three months ended Nine months ended
------------------------ ------------------------
September September September September
30, 30, 30, 30,
2024 2023 2024 2023
----------- ----------- ----------- -----------
Operating
expenses $ 20,073 $ 26,827 $ 74,507 $ 87,914
Impairment -- -- (2,971) --
Restructuring (1,690) -- (3,087) --
------ ------- ------ -------
Non-GAAP
operating
expenses $ 18,383 $ 26,827 $ 68,449 $ 87,914
====== ======= ====== =======
AKOYA BIOSCIENCES, INC. AND SUBSIDIARY
Loss From Operations to Non-GAAP Loss From Operations Reconciliation (unaudited)
(in thousands)
Three months ended Nine months ended
---------------------- ----------------------
September September September September
30, 30, 30, 30,
2024 2023 2024 2023
----------- --------- --------- -----------
Loss from
operations $ (8,349) $(11,551) $(41,018) $(48,229)
Provision for
excess and
obsolete
inventories -
product
discontinuation
and lease exit
inventory
charges -- -- 2,045 --
Impairment -- -- 2,971 --
Restructuring 1,690 -- 3,087 --
------ ------- ------- -------
Non-GAAP loss
from operations $ (6,659) $(11,551) $(32,915) $(48,229)
====== ======= ======= =======
Investor Contact:
Priyam Shah
investors@akoyabio.com
Media Contact:
Christine Quern
media@akoyabio.com
(END) Dow Jones Newswires
November 14, 2024 16:00 ET (21:00 GMT)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.